Genetic determinants of type 2 diabetes mellitus

Clinical Genetics

Volumn 60, Issue 4, 2001, Pages 243-254

  Busch, C P ^a   Hegele, R A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Complex disease; Diabetes; Insulin resistance; Metabolic syndrome; Polygenic trait

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALPAIN; CALPAIN 10; INSULIN; NUCLEOTIDE PYROPHOSPHATASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE I; UNCLASSIFIED DRUG;

ANIMAL MODEL; CHROMOSOME; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; HUMAN; HYPOTHESIS; INSULIN RELEASE; INSULIN RESISTANCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MATURITY ONSET DIABETES MELLITUS; METABOLIC DISORDER; MODULATION; MOLECULAR BIOLOGY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PEDIGREE; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; CALPAIN; CHROMOSOME MAPPING; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPODYSTROPHY; MUTATION; OCEANIC ANCESTRY GROUP;

EID: 0034750833     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2001.600401.x     Document Type: Conference Paper

References (111)

1. Global burden of diabetes 1995-2025
2. From genome to aetiology in a multifactorial disease, type 1 diabetes
3. Clinical practice recommendations 1997
4. Hyperglycemia and microvascular and macrovascular disease in diabetes
5. Risk factors for non-insulin-dependent diabetes
6. The natural history of type 2 diabetes: Implications for clinical practice
7. The insulin resistance-dyslipidemic syndrome of visceral obesity: Effect on patients' risk
8. Pathophysiology of insulin resistance in human disease
9. Strategies and prospects for finding insulin resistance genes
10. Evolution of beta cell dysfunction in the male Zucker diabetes fatty rat
11. The beta-cell in diabetes: From molecular genetics to clinical research
12. Seminars in medicine of the Beth Israel Hospital, Boston: Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance
13. Mutant insulin syndromes
14. Human type 1 diabetes and the insulin gene: Principles of mapping polygenes
15. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes
16. Genetic basis of endocrine disease 1: Molecular genetics of insulin resistant diabetes mellitus
17. Glucose transporters and insulin action: Implications for insulin resistance and diabetes mellitus
18. IRS proteins and beta-cell function
19. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes
20. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neurod-deficient mice
21. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus
22. Adrenoceptor genes in human obesity
23. Leptin and the regulation of body weight in mammals
24. The hormone resistin links obesity to diabetes
25. Single nucleotide polymorphisms of the resistin (RSTN) gene
26. The nuclear receptor PPAR gamma-bigger than fat
27. Thiazolidinediones and insulin resistance: Peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene
28. Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed?
29. Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young
30. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes
31. Diabetes-associated mutations in a beta-cell transcription factor destabilize an antiparallel 'mini-zipper' in a dimerization interface
32. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1
33. Two members of an HNF1 homeoprotein family are expressed in human liver
34. Familial partial lipodystrophy
35. Partial lipoatrophy with insulin resistant diabetes and hyperlipidemia (Dunnigan syndrome)
36. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)
37. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
38. Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy
39. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes
40. Premature atherosclerosis associated with monogenic insulin resistance
41. Maternally inherited diabetes and deafness: A new diabetes subtype
42. Beta 3-adrenergic receptor-mediated lipolysis and oxygen consumption in brown adipocytes from cynomologus monkeys
43. Time of onset of non-insulin dependent diabetes mellitus and genetic variation in the beta-3-adrenergic receptor gene
44. Association of a polymorphism in the beta-3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns
45. Genetic variation in the beta-3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity
46. A mutation of the beta-3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride
47. Polymorphism of the human beta-3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function
48. Familial aggregation of obesity, candidate genes and quantitative trait loci
49. The human obesity gene map: The 1999 update
50. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR-gamma) gene in diabetic Caucasians: Identification of a pro12ala PPAR-gamma-2 missense mutation
51. A pro12ala substitution in PPAR-gamma-2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
52. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis
53. Association of the pro12ala variant in the peroxisome proliferator-activated receptor-gamma-2 gene with obesity in two Caucasian populations
54. Pro12Ala substitution in the peroxisome proliferator-activated receptor is not associated with type 2 diabetes
55. The common PPARgamma Pro12A1a polymorphism is associated with decreased risk of type 2 diabetes
56. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree
57. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women
58. Peroxisome proliferator-activated receptor gamma 2 Pro12A1a gene variant is strongly associated with larger body mass in the Taiwanese
59. The peroxisome proliferator-activated receptor gamma 2 Pro12A1a mutation is associated with early onset extreme obesity and reduced fasting glucose
60. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds
61. Effect of the Pro12A1a variant of the human peroxisome proliferator-activated receptor gamma2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men
62. Homozygosity of the Pro12A1a variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): Divergent modulating effects on body mass index in obese and lean Caucasian men
63. The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects
64. Variation in the gene for human peroxisome proliferator activated receptor gamma (PPARgamma) does not play a major role in the development of morbid obesity
65. The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly dyslipidemia
66. A Pro12A1a polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with hyperlipidaemia in obesity
67. Identification of nucleotide pyrophosphatase/alkaline phosphodiesterase I activity associated with the mouse plasma cell differentiation antigen PC-1
68. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus
69. Increased activity of membrane glycoprotein PC-1 in the fibroblasts from non-insulin-dependent diabetes mellitus patients with insulin resistance
70. Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM): Evidence for increased phosphorylation in pregnancy and GDM
71. Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin
72. Skeletal muscle content of membrane glycoprotein PC-1 in obesity. Relationship to muscle glucose transport
73. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance
74. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis
75. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians
76. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2
77. Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans
78. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families
79. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians
80. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians
81. Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers
82. A genome scan for type 2 diabetes susceptibility loci in a genetically isolated population
83. A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11
84. A genome-wide search for type II diabetes susceptibility genes in Chinese Hans
85. A susceptibility locus for early-onset non-insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, proximal to the phosphoenolpyruvate carboxykinase gene
86. Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans
87. Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians
88. A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes
89. The 3′-untranslated region polymorphism of the gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1 in the type 2 diabetic Japanese population
90. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus
91. Genetic variation in LMNA modulates plasma leptin and indices of obesity in aboriginal Canadians
92. Common genomic variation in LMNA modulates indexes of obesity in Inuit
93. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is associated with a common polymorphism in LMNA in Pima Indians
94. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
95. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance
96. Reduced skeletal muscle calpain-10 transcript level is due to a cumulative decrease in major isoforms
97. Absence of association of type 2 diabetes with CAPN10 and PC-1 polymorphisms in Oji-Cree
98. Geographical distribution of diabetes among the native population of Canada: A national survey
99. The prevalence of NIDDM and associated risk factors in native Canadians
100. The hepatic nuclear factor-1alpha G319S variant is associated with early onset type 2 diabetes in Canadian Oji-Cree
101. Youth-onset type 2 diabetes (Y2DM) associated with HNF1A S319 in aboriginal Canadians
102. Clinical utility of HNF1A genotyping for diabetes in aboriginal Canadians
103. Genes and environment in type 2 diabetes and atherosclerosis in aboriginal Canadians
104. Disparity between association and linkage analysis for HNF1A G319S in type 2 diabetes in Canadian Oji-Cree
105. The molecular genetics of rodent single gene obesities
106. Insights into insulin resistance and type 2 diabetes from knockout mouse models
107. Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: What can we learn from transgenic and knockout mice?
108. Disease model: Hyperinsulinemia and insulin resistance
109. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1
110. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance
111. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy